Introduction
============

Type I diabetes patients present an increased risk of developing cardiovascular diseases relative to the general population ([@B5]). Furthermore, coronary artery disease represents the leading cause of death among patients with diabetes mellitus ([@B27]). In fact, children with type 1 diabetes exhibit increased aortic intima-media thickness, an early marker of subclinical atherosclerosis ([@B14]). Studies in animal models, such as atherosclerosis susceptible mice, have revealed that hyperglycemia is associated with increased aortic sinus atherosclerosis ([@B24]; [@B34]; [@B35]; [@B17]; [@B31]; [@B33]; [@B2]). However, the effects of hyperglycemia on coronary artery atherosclerosis are less well-studied, in part because conventional mouse atherosclerosis models, such as apolipoprotein E (apoE) or LDLR deficient mice, do not develop substantial coronary artery atherosclerosis or subsequent myocardial infarction ([@B11]; [@B30]).

Mice deficient in the HDL receptor, SR-B1, exhibit substantially increased HDL cholesterol as a result of impaired hepatic HDL cholesterol clearance ([@B26]). Mice deficient in both SR-B1 and apo E, *SR-B1/apoE* double KO mice, exhibit accelerated aortic sinus atherosclerosis development ([@B29]) as well as spontaneous development of extensive, occlusive atherosclerosis in coronary arteries, myocardial infarction, and early death (∼6--8 weeks of age; [@B3]). We and others reported similar results for mice deficient in both SR-B1 and the LDLR (*SR-B1/LDLR* double KO mice) fed HFC atherogenic diets ([@B9]; [@B21]). *SR-B1* KO mice homozygous for a hypomorphic mutant apoE allele (*hypoE*) also develop HFC diet-induced coronary artery atherosclerosis, myocardial infarction, cardiac dysfunction, and reduced survival ([@B38]; [@B23]; [@B15]; [@B22]). Taking advantage of the inducible nature of the coronary artery atherosclerosis and myocardial infarction in *SR-B1-KO/hypoE* mice, we tested whether the induction of hyperglycemia in these mice affected the development of the diet induced coronary heart disease phenotype.

Hyperglycemia was induced by treatment of *SR-B1-KO/hypoE* mice with STZ. We report that multiple low dose STZ-treatment was not sufficient to induce coronary artery atherosclerosis in *SR-B1-KO/hypoE* mice fed a normal low fat/low cholesterol diet, and did not increase the extent of HFC diet induced coronary artery atherosclerosis. However, it did increase atherosclerotic plaque sizes and the sizes of necrotic cores in atherosclerotic plaques in the aortic sinus, and increased the extent of platelet accumulation in atherosclerotic coronary arteries in HFC diet fed *SR-B1-KO/hypoE* mice. Furthermore, STZ-treatment substantially increased cardiac fibrosis, and reduced the survival of HFC diet fed *SR-B1-KO/hypoE* mice. These findings suggest that STZ-induced hyperglycemia increased plaque thrombosis and myocardial infarction independently of alterations in atherosclerosis development in coronary arteries and suggest that HFC diet fed *SR-B1-KO/hypoE* mice may be a useful non-surgical model for hyperglycemia-induced plaque thrombosis and myocardial infarction.

Materials and Methods {#s1}
=====================

Materials
---------

Citrate buffer was purchased from Electron Microscopy Sciences (Hatfield, PA, United States). STZ and all other materials were purchased from Sigma Aldrich (St. Louis, MO, United States) unless indicated otherwise.

Animals
-------

All procedures were approved by the McMaster University Animal Research Ethics Board in accordance with the Canadian Council on Animal Care. Mice were housed in the Thrombosis and Atherosclerosis Research Institute (TaARI) animal facility in a *Helicobacter sp.* and murine noravirus positive room under controlled light (12 h light/dark) and temperature conditions. Mice were bred and housed in ventilated cages, had free access to food and received automatic watering. *SR-B1^-/-^*;*apoE-R61^hypomorphic^* (*SR-B1-KO/hypoE*) mice (mixed *C57BL/6:129* background) were produced by mating female *SR-B1^+/-^/hypoE* and male *SR-B1-KO/hypoE* mice from founders originally obtained from Monty Krieger (Massachusetts Institute of Technology, Cambridge, MA, United States; [@B38]; [@B25]). Experimental mice were housed 2--4/cage. To induce diabetes, 5- or 8-weeks-old mice were given daily i.p. injections of STZ (40 mg/kg body weight in 20 μl) for 5 days, were rested for 1 week, and then received another series of five daily injections of STZ; control mice received vehicle (20 μl of 20 mmol/l citrate) following the same schedule ([@B35]). Non-fasting blood glucose was monitored weekly (see below). Mice with confirmed hyperglycemia were kept in the study, whereas mice whose blood glucose levels returned to baseline were removed. All mice in the study were males because we initially experienced difficulty in reproducibly inducing hyperglycemia in female mice. Mice were fed either normal rodent chow (Harlan Teklad TD2018, Madison, WI, United States) throughout the study, or, 3 weeks after initiation of STZ or control citrate buffer injection, mice were switched to a HFC diet (Harlan Teklad TD94059, Madison, WI, United States), containing 15.8% (by weight) fat and 1.25% (by weight) cholesterol. Mice that were to be fed the HFC diet were treated with STZ or control citrate buffer starting at 5 weeks of age, whereas mice that were maintained on normal chow throughout the study were treated with STZ or control citrate buffer beginning at 8 weeks of age. For survival studies, mice fed the HFC diet were monitored until they reached humane endpoint at which point they were euthanized ([@B9]). Otherwise, mice fed the HFC diet were fasted for 4 h and sacrificed 7 weeks after the start of STZ- or control citrate buffer injection (4 weeks of HFC diet feeding) or, for mice maintained on normal chow diet, 14 weeks after the start of STZ- or control citrate buffer injection.

Blood and Plasma Analysis
-------------------------

Plasma total cholesterol was measured using the Infinity Total Cholesterol assay kit (ThermoFisher Scientific, Burlington, ON, Canada). Unesterified cholesterol was measured using the Free Cholesterol E assay kit (Wako Diagnostics, Richmond VA, United States). Cholesteryl ester levels were calculated as the difference between total cholesterol and unesterified cholesterol measurements. HDL-cholesterol was measured with the HDL-Cholesterol E assay kit (Wako Diagnostics, Richmond VA, United States). Triglyceride was measured with the Infinity Triglycerides Liquid Stable assay kit (ThermoFisher Scientific, Burlington, ON, Canada). IL-6 and TNF-α were measured by ELISA (Biolegend, San Diego, CA, United States). Blood glucose was measured using a commercial glucometer (Contour Glucose Meter, Bayer). We observed that the high lipid levels in samples from mice fed the HFC diet appeared to interfere with the glucose measurements. To control for this, a standard curve was constructed by spiking plasma from HFC diet fed mice with known concentrations of added glucose.

Histology
---------

Cryosections (10 μm thick) from the top half (base) of the heart and the aortic sinus were stained with oil red O and hematoxylin, hematoxylin and eosin or Masson's Trichrome, as previously described([@B1]; [@B25]; [@B9]; [@B37]). Aortic sinus atherosclerosis and coronary artery atherosclerosis burden were measured in oil red O and hematoxylin-stained sections as previously described ([@B1]; [@B25]; [@B9]; [@B37]). Necrotic core sizes were measured as the a-nuclear and a-cellular areas within hematoxylin and eosin-stained plaques and were normalized to plaque area, as previously described ([@B10]; [@B36]). Myocardial fibrosis was detected in transverse sections of hearts with Masson's Trichrome, which stains collagen-rich tissue blue and healthy myocardium red. Images of Trichrome-stained transverse heart sections are composites taken at 10 × magnification with an Olympus BX41 microscope and assembled using Slidebook 5.0 software. Percentage of myocardial fibrosis was quantified as previously described ([@B1]; [@B25]; [@B9]; [@B37]).

Immunofluorescence
------------------

Tissue sections were stained with rat anti-mouse CD41 antibody (catalog number 553847, BD Pharmingen, Mississauga, ON, Canada) followed by alexa 488-conjugated goat anti-rat IgG (catalog number A-11006, Invitrogen, ThermoFisher Scientific, Burlington, ON, Canada). Periostin was detected by immunofluorescence using a rabbit anti-periostin polyclonal antibody (catalog number ab92460, Abcam Inc., Toronto, ON, Canada) followed by alexa 488-conjugated goat anti-rabbit IgG (catalog number A-11008, Invitrogen, ThermoFisher Scientific, Burlington, ON, Canada). Sections were counterstained with DAPI to visualize nuclei. All images were acquired with a Zeiss Axiovert 200M inverted microscope with a 20 or 40x objective. CD41-positive coronary arteries were counted across five tissue sections. Results were expressed as the average number of CD41-positive coronary arteries per tissue section.

Statistical Analysis
--------------------

Results are presented as mean ± standard error of the mean (SEM). Survival curves were analyzed by the Mantel-Cox log-rank test. For comparison of two groups, data were subjected to the Mann--Whitney rank sum test as indicated. To analyze significant differences between more than two groups, one-way ANOVA followed by Tukey multiple comparisons test or two-way ANOVA followed by Sidak's multiple comparisons *post hoc* test were used. Statistical analysis was performed using PRISM software (GraphPad Software Inc., La Jolla, CA, United States). *P* \< 0.05 was considered to be significant.

Results
=======

Effects of STZ-Treatment of *SR-B1-KO/hypoE* Mice on Hyperglycemia and Plasma Lipids
------------------------------------------------------------------------------------

The experimental scheme is shown in **Figure [1A](#F1){ref-type="fig"}**. *SR-B1-KO/hypoE* mice that were treated with STZ exhibited increased blood glucose levels beginning 2--3 weeks after the start of STZ injections (**Figure [1B](#F1){ref-type="fig"}**). Occasionally, we observed individual mice whose blood glucose levels returned to baseline levels after STZ treatment was discontinued; those were removed from the study. Blood glucose levels did not increase in *SR-B1-KO/hypoE* mice injected with citrate buffer vehicle (denoted as "control"; **Figure [1B](#F1){ref-type="fig"}**). We saw no differences in blood glucose levels between STZ-treated mice that had been maintained on a normal chow diet or mice that had been fed the HFC diet. Mice that were maintained on normal chow, regardless of treatment with STZ or control citrate buffer, exhibited no obvious clinical signs (other than dramatically increased urination in the STZ treated mice) and survived to the end of the study (14 weeks after initiation of STZ or control citrate buffer treatment; **Figure [1C](#F1){ref-type="fig"}**) at which point, they were euthanized for further analysis. *SR-B1-KO/hypoE* mice are known to develop HFC diet induced occlusive coronary artery atherosclerosis and fatal myocardial infarction ([@B38]; [@B23]; [@B25]; [@B15]; [@B22]). Consistent with this, *SR-B1-KO/hypoE* mice that had been treated with control citrate buffer and switched to the HFC diet exhibited reduced survival, with a median survival of 11.3 weeks after the start of treatment (8.3 weeks after the start of HFC diet feeding). The reduced survival of *SR-B1-KO/hypoE* mice that had been treated with STZ was even more pronounced, with a median survival of 9 weeks after the start of STZ treatment (6 weeks after the start of HFC diet feeding). Thus, STZ-treated *SR-B1-KO/hypoE* mice exhibited a greater reduction in survival in response to the HFC diet than control-treated mice.

![STZ-induced diabetes is associated with reduced survival HFC diet fed *SR-B1-KO/hypoE* mice. **(A)** Schematic representation of experimental time course. Male mice were treated with two rounds of low dose (40 mg/kg body weight) STZ injections (daily for 5 days each round) during weeks 1 and 3 (small arrows). Control mice received citrate buffer (not shown). At week 3, mice were fed either a HFC diet containing 15% fat and 1.25% cholesterol, or were maintained on a normal chow diet. Mice were either euthanized for analysis at week 7 (after 4 weeks of feeding the HFC diet; black arrow), week 14 (for normal chow diet; gray arrow) or were monitored for surrogate endpoint at which time they were humanly euthanized. **(B)** Non-fasting blood glucose levels over the course of the study for*(control- (circles) or STZ-treated mice (squares) fed either the normal chow (gray symbols) or switched to the HFC diet (white arrow; black symbols). Symbols represent means ± SEM of *n* = 7 (control-treated, fed normal chow), *n* = 6 (STZ-treated, fed normal chow), *n* = 14 (control-treated, fed HFC diet), and *n* = 15 (STZ-treated, fed HFC diet). Data were subjected to two-way ANOVA; *p* \< 0.0001 for control- vs STZ-treated mice fed each diet, and for STZ-treated mice fed normal chow vs HFC diet. **(C)** Survival to surrogate endpoint for control- (circles) or STZ-treated mice (squares) fed either the normal chow diet (gray symbols) or the HFC diet (black symbols). The vertical dashed line and white arrow indicates the start of HFC diet feeding at 3 weeks (after start of STZ- or control citrate buffer treatment). *P* \< 0.0001 for comparison between mice fed the normal chow and HFC diets and *p* = 0.009 for control- vs STZ-treated mice fed the HFC diet (by Mantel--Cox log-rank test).)*](fphys-09-01398-g001){#F1}

High fat/high cholesterol diet feeding significantly increased total and unesterified cholesterol, cholesteryl ester, and non-HDL cholesterol and reduced HDL cholesterol in plasma of *SR-B1-KO/hypoE* mice (**Figures [2A](#F2){ref-type="fig"}--[E](#F2){ref-type="fig"}**). STZ-treatment did not affect plasma cholesterol levels in *SR-B1-KO/hypoE* mice maintained on normal chow (other than slightly increasing mean HDL cholesterol levels), but was associated with a 20% increase in average plasma levels of total cholesterol, and cholesteryl ester in *SR-B1-KO/hypoE* mice fed the HFC diet (**Figures [2A](#F2){ref-type="fig"}--[E](#F2){ref-type="fig"}**). A similar trend toward increased mean non-HDL cholesterol was seen in STZ- vs control-treated mice fed the HFC diet but this did not reach statistical significance by one-way ANOVA (although it did appear to reach significance when only the control and STZ-samples for HFC diet fed mice were analyzed; **Figures [2A](#F2){ref-type="fig"}--[E](#F2){ref-type="fig"}**). Similarly, trends toward increased triglyceride levels were observed in STZ-treated compared to control-treated mice. For mice maintained on the normal chow diet, these were just shy of significance (**Figure [2F](#F2){ref-type="fig"}**). HFC diet feeding was associated with statistically significantly increased plasma IL-6 levels in mice treated with STZ. For mice fed the HFC diet, there was a trend toward higher mean IL-6 levels for STZ- compared to control-treated mice (although this did not reach statistical significance; **Figure [2G](#F2){ref-type="fig"}**). No differences were detected in plasma TNF-α levels between STZ- and control-treated mice fed the HFC diet (**Figure [2H](#F2){ref-type="fig"}**).

![Plasma lipids and IL-6 in control- and STZ-treated *SR-B1-KO/hypoE* mice fed the normal chow or HFC diets. Mice were fasted for 4 h prior to humane euthanasia under anesthesia, and blood collection by cardiac puncture into heparinized syringes. Plasma was analyzed for total cholesterol **(A)**, unesterified cholesterol **(B)**, cholesteryl ester (total-unesterified cholesterol; **C**), HDL cholesterol **(D)**, non-HDL cholesterol (total -- HDL cholesterol; **E)**, triglycerides **(F)** IL-6 **(G)**, and TNF-α **(H)** using commercially available assay kits as described in Section "Materials and Methods." Circles represent mice treated with control citrate buffer (Cntrl) and squares represent mice treated with STZ. Gray symbols represent mice maintained on normal chow up to 14 weeks after start of control/STZ-treatment and black symbols represent mice switched to HFC diet 3 weeks after start of control/STZ-treatment and analyzed after 4 weeks of HFC diet feeding. Horizontal bars and error bars represent means and SEM. Data were analyzed by one-way ANOVA with the Tukey's multiple comparisons test; ns indicates not statistically significant; ^∗^*p* \< 0.05, ^∗∗∗^*p* \< 0.001; ^∗∗∗∗^*p* \< 0.00001. Pairwise comparisons indicated by the symbols \#, §, and ¶were done using the Mann--Whitney rank sum test. ^\#^*p* = 0.02; ^§^*p* = 0.051; ^¶^*p* = 0.061.](fphys-09-01398-g002){#F2}

Effect of STZ-Treatment on HFC Diet-Induced Atherosclerosis in *SR-B1-KO/hypoE* Mice
------------------------------------------------------------------------------------

To examine the effects of STZ-treatment on atherosclerosis in *SR-B1-KO/hypoE* mice, we first examined atherosclerotic plaque sizes in the aortic sinus of mice maintained on a normal chow diet and euthanized 14 weeks after the start of STZ-treatment. Mice treated with control citrate buffer and then maintained on a normal chow diet developed atherosclerotic plaques in the aortic sinus, with an average ± SEM plaque cross-sectional area of 78,000 ± 12,000 μm^2^. Surprisingly, mice treated with STZ and maintained on a normal chow diet had smaller aortic sinus atherosclerotic plaque sizes with an average of 33,000 ± 7,000 μm^2^ (**Figures [3A](#F3){ref-type="fig"}--[C](#F3){ref-type="fig"}**). When mice were fed the HFC diet beginning 3 weeks after the start of STZ or control citrate buffer treatment, and then euthanized for analysis at week 7 (4 weeks after the start of HFC diet feeding), the average atherosclerotic plaque cross-sectional area in the aortic sinus reached 97,600 ± 14,700 μm^2^ for mice treated with control citrate buffer and 145,000 ± 15,300 μm^2^ for mice treated with STZ (**Figures [3D](#F3){ref-type="fig"}--[F](#F3){ref-type="fig"}**). Therefore, STZ-treatment was associated with a statistically significant, 50% increase in average diet-induced atherosclerosis in the aortic sinus of *SR-B1-KO/hypoE* mice. Similarly, STZ-treated mice fed the HFC diet exhibited a significant increase in the average necrotic core size (26.5 ± 1.9 vs 14.9 ± 2.2% of plaque size for STZ- vs control-treated mice that had been fed the HFC diet; **Figures [3G](#F3){ref-type="fig"}--[I](#F3){ref-type="fig"}**). This is consistent with observations that STZ-treatment increases high fat diet-induced atherosclerosis in other mouse models such as low density receptor-deficient mice ([@B34]; [@B17]; [@B2]).

![Effects of STZ-treatment on atherosclerosis in the aortic sinus. **(A,B)** Representative images of oil red O/hematoxylin-stained cross sections of the aortic sinus of control- and STZ-treated mice maintained on the normal chow diet up to 14 weeks after the start of STZ-treatment. Scale bars represent 100 μm. **(C)** Quantification of atherosclerotic plaque area (*n* = 7 control- and 6 STZ-treated mice; ^∗^*p* = 0.01). **(D,E)** Representative images of oil red O/hematoxylin-stained cross sections of the aortic sinus of control- and STZ-treated mice switched to the HFC diet 3 weeks after the start of STZ-treatment, and analyzed after 4 weeks of HFC diet feeding. Scale bars represent 100 μm. **(F)** Quantification of atherosclerotic plaque area (*n* = 14 control- and 15 STZ-treated mice; ^∗^*p* = 0.02). **(G,H)** Representative images of hematoxylin and eosin-stained atherosclerotic plaques in the aortic sinus of control and STZ-treated mice after 4 weeks of HFC diet feeding, showing necrotic cores devoid of nuclei and cells. Scale bars represent 50 μm. **(I)** Quantification of necrotic core area expressed as a percentage of the total plaque cross-sectional area per section (*n* = 14 control and 15 STZ treated mice; ^∗∗∗^*p* = 0.008). Data were analyzed by the Mann--Whitney rank sum test.](fphys-09-01398-g003){#F3}

*SR-B1-KO/hypoE* mice fed the HFC diet develop atherosclerosis in coronary arteries in addition to the aortic sinus ([@B38]; [@B23]; [@B25]; [@B15]; [@B22]). We therefore examined the effects of STZ- vs control-treatment on atherosclerosis in coronary arteries in *SR-B1-KO/hypoE* that had been maintained on chow diet until 14 weeks after the induction of STZ or control- treatment, and in STZ- or control-treated *SR-B1-KO/hypoE* mice that had been fed the HFC diet beginning 3 weeks after the start of STZ- or control-treatment for a total of 4 weeks of HFC diet feeding (**Figures [4A](#F4){ref-type="fig"}--[G](#F4){ref-type="fig"}**). To evaluate the extent of coronary artery atherosclerosis, coronary arteries were identified in oil red O/hematoxylin stained sections from the base of the aortic sinus to the midpoint of the heart and the numbers of coronary arteries exhibiting either no atherosclerosis, evidence of fatty streaks, or atherosclerotic plaques occluding less than 50%, greater than 50%, or 100% of the lumen of the coronary artery (**Figures [4A](#F4){ref-type="fig"}--[E](#F4){ref-type="fig"}**) were counted. STZ- or control-treated mice maintained on normal chow until 14 weeks after the start of STZ-treatment exhibited few atherosclerotic coronary arteries, with \>80--90% of coronary arteries exhibiting no atherosclerosis (**Figure [4F](#F4){ref-type="fig"}**). In contrast, STZ- and control-treated mice that had been fed the HFC diet for 4 weeks before analysis exhibited numerous atherosclerotic coronary arteries, with on average 60 and 50% of coronary arteries per section exhibiting no atherosclerosis and on average 22 and 27% of coronary arteries per section exhibiting full occlusion of their lumen (**Figure [4G](#F4){ref-type="fig"}**). Surprisingly, STZ-treatment appeared to slightly reduce the small number of atherosclerotic and slightly increase the number of non-atherosclerotic coronary arteries in chow fed mice, while it slightly increased the number of atherosclerotic and slightly reduced the number of non-atherosclerotic coronary arteries in the mice fed the HFC diet. Nevertheless, the effect of STZ-treatment on the number of fully occluded coronary arteries in the HFC diet fed mice appeared to be modest and did not reach statistical significance (although the reduction in the number of coronary arteries that were not atherosclerotic did). Therefore, STZ-treatment was associated with only a modest effect on coronary artery atherosclerosis in HFC diet fed mice. We detected no apparent differences in the appearance of fully occluded, atherosclerotic coronary arteries either upon oil red O/hematoxylin staining (not shown) or trichrome staining (**Figures [4H,I](#F4){ref-type="fig"}**). However, immunostaining for CD41, a marker of activated platelets (**Figures [4J,K](#F4){ref-type="fig"}**), revealed that there was a greater number of occluded coronary arteries that were CD41-positive from STZ-treated compared to control citrate buffer-treated *SR-B1-KO/hypoE* mice that had been fed the HFC diet for 4 weeks (**Figure [4L](#F4){ref-type="fig"}**). This suggested increased platelet accumulation in atherosclerotic coronary arteries from the STZ-treated mice fed the HFC diet.

![HFC diet-induced atherosclerosis and platelet accumulation in coronary arteries of control and STZ-treated *SR-B1-KO/hypoE* mice. Heart cross sections were stained with oil red O and hematoxylin. **(A--E)** Representative images of coronary arteries classified as having no atherosclerotic plaques ("plaque free"), fatty streaks (arrows), identified as oil red O staining within the wall without the presence of raised plaque, or containing raised atherosclerotic plaques occluding \<50, \>50, or 100% of the artery lumen (as shown). Quantification of the average proportions of coronary arteries per section classified according to the degree of occlusion in control- (circles) or STZ-treated mice (squares) **(F)** maintained on normal chow diet for 14 weeks after the start of control- or STZ-treatment (*n* = 7 and 6, respectively); or **(G)** switched to the HFC diet 3 weeks after start of treatment and analyzed after 4 weeks of HFC diet feeding (*n* = 14 and 15, respectively). Representative images of trichrome stained occluded coronary arteries from control- **(H)** or STZ-treated mice **(I)** fed the HFC diet for 4 weeks. Representative images of atherosclerotic CA's stained for activated platelets (CD41, green) and nuclei (DAPI, blue) showing an atherosclerotic coronary artery that is negative **(J)** and an atherosclerotic coronary artery that is positive **(K)** for CD41 staining. The dashed line represents the vessel wall. **(L)** Quantification of the numbers of CD41^+^ atherosclerotic coronary arteries per section for control-treated (*n* = 11, circles) and STZ-treated mice that had been fed the HFC diet for 4 weeks (*n* = 14, squares). Scale bars represent 50 μm. Data in **F** and **G** were analyzed by two-way ANOVA with Sidak's multiple comparisons test. Data in **L** were analyzed by the Mann--Whitney rank sum test. ^∗^*p* = 0.017; ^∗∗^*p* \< 0.01, ^∗∗∗∗^*p* \< 0.0001. All other comparisons between control- and STZ-treated samples from **F** and **G** were not statistically significantly different.](fphys-09-01398-g004){#F4}

STZ-Treatment Increases HFC Diet-Induced Cardiac Fibrosis in *SR-B1-KO/hypoE* Mice
----------------------------------------------------------------------------------

Trichrome staining of cardiac sections revealed that neither STZ- nor control-treated mice maintained on the normal chow diet exhibited detectable cardiac fibrosis (**Figures [5A,B,E](#F5){ref-type="fig"}**). In contrast, both control- and STZ-treated mice that had been fed the HFC diet for 4 weeks before sacrifice exhibited substantial cardiac fibrosis evident as the purple-blue staining of collagen (healthy myocardial tissue stains red; **Figures [5C](#F5){ref-type="fig"}--[E](#F5){ref-type="fig"}**). A greater extent of cardiac fibrosis (measured as the percentage of the cardiac cross section that was stained blue) was seen in the HFC diet fed mice that had been treated with STZ compared to the control, citrate buffer (11.9 ± 2.6 vs 4.0 ± 0.8% of the cross-sectional area stained for collagen, **Figure [5E](#F5){ref-type="fig"}**). Immunostaining for periostin, a matricellular protein that regulates cardiac fibrosis ([@B8]; [@B19]) -- revealed increased levels in the myocardial tissue of STZ- compared to control-treated *SR-B1-KO/hypoE* mice that were fed the HFC diet (**Figures [5F](#F5){ref-type="fig"}--[I](#F5){ref-type="fig"}**). Despite the increased fibrosis, neither heart weights nor heart/body weight ratios were significantly different between the STZ- or control-treated mice fed either the normal chow or the HFC diet (**Figures [5J](#F5){ref-type="fig"}--[L](#F5){ref-type="fig"}**). This suggests that the 4 week HFC feeding period may not have been long enough for the development of cardiomegaly, consistent with previous observations that cardiomegaly appears to develop after cardiac fibrosis and later in the disease process, closer to the sudden death of these mice ([@B25]).

![Effects of STZ- treatment on myocardial fibrosis in HFC diet fed *SR-B1-KO/hypoE* mice. Representative composite images of cardiac cross sections from **(A)** control- and **(B)** STZ-treated mice fed the normal chow diet and analyzed 14 weeks after the start of treatment, or **(C)** control- and **(D)** STZ-treated mice fed the HFC diet beginning 3 weeks after the start of treatment and analyzed after 4 weeks of HFC diet feeding. Sections are stained with Mason's trichrome -- healthy myocardium stains red and collagen stains blue (arrows). Scale bars represent 1.5 mm. **(E)** Quantification of average fibrotic (blue) area per section. Representative images of periostin staining (green) of cardiac sections from **(F)** control- and **(G)** STZ-treated mice fed the HFC diet beginning 3 weeks after the start of treatment and analyzed after 4 weeks of HFC diet feeding. **(H)** Control section of heart from an STZ-treated mouse fed the HFC diet in which the primary anti-periostin antibody was left out. Sections were counterstained with DAPI (blue). Scale bars represent 25 μm. **(I)** Quantification of periostin staining intensity per cardiac cross-sectional area for control- or STZ-treated mice that had been fed the HFC diet. **(J)** Heart weights, **(K)** body weights, and **(L)** heart/body weight ratios for control-treated (circles) and STZ-treated mice (squares) either maintained on the normal chow diet for 14 weeks after control/STZ-treatment (gray symbols) or fed the HFC diet for 4 weeks, beginning 3 weeks after control/STZ-treatment (black symbols). Each symbol in **E** and **I--L** represents an individual mouse. Means ± SEM are indicated by the horizontal lines and error bars. Data in **E** and **J--L** were analyzed by one-way ANOVA with Tukey's multiple comparisons test and data in **I** were analyzed by the Mann--Whitney rank sum test; ns indicates not statistically significantly different (*p* \> 0.05; ^∗^*p* = 0.018; ^∗∗^*p* = 0.005).](fphys-09-01398-g005){#F5}

Discussion
==========

*SR-B1-KO* mice containing atherogenic mutations in either apoE (*KO* or hypomorphic) or LDLR (*LDLR-KO*) develop either spontaneous (in the case of SR-B1/apoE double KO) or HFC diet-induced (in the case of *SR-B1-KO/hypoE* or *SR-B1/LDLR double KO* mice) coronary artery atherosclerosis, myocardial infarction, and dramatically reduced survival ([@B3], [@B4]; [@B38]; [@B18]; [@B23]; [@B1]; [@B9]; [@B15]; [@B22]; [@B21]). The reduced survival of these mice appears to be associated with myocardial infarction and resulting cardiac conduction and functional abnormalities ([@B3], [@B4]; [@B38]; [@B18]; [@B23]; [@B1]; [@B9]; [@B15]; [@B22]; [@B21]). In the case of the *SR-B1-KO/hypoE* and *SR-B1/LDLR double KO* mice, the timing of the onset of these phenotypes is dependent on the composition of the diet, with respect to fat and cholesterol and other components (such as cholate) which affect the diet's atherogenicity ([@B23]; [@B9]). Hyperglycemia is a risk factor for atherosclerotic disease in humans ([@B14]; [@B27]; [@B5]), and has been shown to accelerate either spontaneous (*apoE-KO* mice), or diet-induced atherosclerosis (both *apoE-KO* and *LDLR-KO* mice) ([@B24]; [@B34]; [@B35]; [@B17]; [@B31]; [@B33]; [@B2]). We therefore set out to test if hyperglycemia, alone, was sufficient to trigger coronary artery atherosclerosis development and myocardial infarction in *SR-B1-KO/hypoE* mice maintained on a normal chow diet, or to increase the onset of these phenotypes in these mice fed the HFC diet. To induce hyperglycemia, we exposed the mice to multiple low doses of STZ. STZ-treatment alone, in the absence of HFC diet, was not sufficient to trigger the development of coronary artery atherosclerosis (**Figure [4F](#F4){ref-type="fig"}**) or associated phenotypes, such as myocardial infarction (**Figures [5A,B,E](#F5){ref-type="fig"}**) and reduced survival (**Figure [1B](#F1){ref-type="fig"}**), at least within the 14 week timeframe of our study. By comparison, reduced survival of the control-treated *SR-B1-KO/hypoE* mice fed the HFC diet was seen as early as 5 weeks after the start of HFC diet feeding, with the median survival being 8.3 weeks after the start of HFC diet feeding (**Figure [1B](#F1){ref-type="fig"}**).

Surprisingly, we saw that STZ-treatment was associated with a reduction in spontaneous atherosclerosis development as measured by cross-sectional area of atherosclerotic plaques in the aortic sinus of *SR-B1-KO/hypoE* mice fed the normal chow diet. This is surprising given the literature that demonstrates that STZ-treatment generally increases spontaneous and high fat diet-induced atherosclerosis in *apoE-KO* and/or *LDLR-KO* mice ([@B24]; [@B34]; [@B35]; [@B17]; [@B31]; [@B33]; [@B2]). It has, however, been reported that STZ-mediated induction of aortic sinus atherosclerotic plaque development in *apoE-KO* mice appears to be time dependent, with STZ-treatment exhibiting more pronounced effects early in atherosclerosis development and diminished effects with increased time ([@B31]). Therefore, it is possible that the apparent protection against aortic sinus atherosclerosis observed by STZ-treatment in the normal chow diet fed *SR-B1-KO/hypoE* mice may be a feature of the timing of our analysis with respect to the start of STZ-treatment. Alternatively, we cannot rule out the possibility that this may represent unanticipated effects of STZ-treatment (e.g., other than the induction of hyperglycemia) or a unique response of these *SR-B1-KO/hypoE* mice to STZ-treatment.

Notwithstanding the above observations, we did observe that STZ-treatment was associated with increased sizes of aortic sinus atherosclerotic plaques and of necrotic cores within those plaques in the *SR-B1-KO/hypoE* mice fed the HFC diet (**Figure [3](#F3){ref-type="fig"}**). This is in agreement with previous reports of the effects of STZ and other approaches to induction of hyperglycemia in other mouse models of diet-induced atherosclerosis ([@B34]; [@B16]; [@B17]; [@B2]; [@B32]). Surprisingly, STZ-induced hyperglycemia did not substantially affect the burden of coronary artery atherosclerosis development in the HFC diet fed *SR-B1-KO/hypoE* mice, measured as the numbers of atherosclerotic coronary arteries (**Figure [4G](#F4){ref-type="fig"}**). However, it was associated with substantially increased platelet accumulation in the atherosclerotic coronary arteries of the HFC diet fed *SR-B1-KO/hypoE* mice (**Figures [4J](#F4){ref-type="fig"}--[L](#F4){ref-type="fig"}**). This is in agreement with studies demonstrating increased incidence of coronary thrombosis in diabetic patients ([@B28]). STZ-treated mice fed the HFC diet also exhibited more extensive myocardial fibrosis as detected by trichrome staining (**Figures [5C](#F5){ref-type="fig"}--[E](#F5){ref-type="fig"}**). Consistent with increased fibrosis, they exhibited increased abundance of periostin (**Figures [5F](#F5){ref-type="fig"}--[I](#F5){ref-type="fig"}**), a transforming growth factor β-inducible matricellular protein known to play an important role in cardiac fibrosis and induced post-myocardial infarction and in diabetic cardiomyopathy ([@B8]; [@B13]; [@B19]). Periostin has been reported to be induced in response to myocardial infarction and during diabetic cardiomyopathy and to play an important signaling role in driving cardiac fibrosis ([@B8]; [@B13]; [@B19]). The observation that STZ-treated mice exhibit increased periostin staining in their myocardium compared to control-treated mice in response to HFC diet feeding is consistent with enhanced cardiac remodeling in response to hyperglycemia. Diabetes (both types 1 and 2) has been shown to induce diabetic cardiomyopathy, including enhancing myocardial fibrosis in rodent models of coronary artery ligation-induced ischemia/reperfusion injury ([@B12]; [@B6],[@B7]; [@B20]). Thus, it is possible that the increased cardiac fibrosis seen in STZ- compared to control-treated *SR-B1-KO/hypoE* mice fed the HFC diet may reflect a direct effect of hyperglycemia on cardiac fibrosis.

Alternatively, the increased coronary artery thrombosis may have contributed to the increased cardiac fibrosis. For example, [@B15] recently reported that coronary arteries from *SR-B1-KO/hypoE* mice, fed a more atherogenic diet containing cholate, exhibited features of plaque rupture, including intraluminal thrombi and pro-inflammatory phenotypes, and that their distribution corresponded to regions of hearts exhibiting infarction. Administration of acetylsalicylic acid to those mice resulted in no changes in the burden of coronary artery atherosclerosis but a significantly reduced coronary artery inflammation and thrombosis and myocardial infarction and extended survival of the mice ([@B15]). In an analogous manner, the increased coronary artery thrombosis detected in the STZ- compared to control-treated mice fed the HFC diet may have contributed to the increased cardiac fibrosis and their reduced survival.

We have previously shown that platelet accumulation in atherosclerotic coronary arteries and myocardial fibrosis were both reduced in *SR-B1/apoE* dKO mice treated with the hydroxymethylglutaryl coenzyme A reductase inhibitor, rosuvastatin ([@B37]). In that study, however, we found that rosuvastatin-treatment had additional effects other than reducing platelet accumulation in atherosclerotic coronary arteries; these included reducing atherosclerotic plaque development in the aortic sinus and coronary arteries and reducing the accumulation of oxidized lipids in both the aortic sinus and coronary arteries. Rosuvastatin did not, however, reduce the hypercholesterolemia in the *SR-B1/apoE* dKO mice; instead, plasma total cholesterol levels were, unexpectedly, substantially increased by rosuvastatin treatment; however, the reasons for this effect remain unclear ([@B37]). In the present study, we found that STZ-treatment increased the mean plasma total cholesterol levels in HFC diet fed *SR-B1-KO/hypoE* mice by approximately 20% (**Figure [2A](#F2){ref-type="fig"}**). This appeared to be due to increased levels of cholesterol ester (**Figure [2C](#F2){ref-type="fig"}**) and largely reflected similar trends towards increased cholesterol in the non-HDL fraction. STZ-treatment was also associated with trends towards increased triglyceride levels in normal chow and HFC-diet fed mice, and IL-6, but not TNF-α in the HFC diet fed mice; however, these did not reach statistical significance (**Figures [2F,G](#F2){ref-type="fig"}**). The STZ-induced increase in plasma cholesterol levels in the HFC diet fed mice may also have contributed to the increased aortic sinus atherosclerosis, coronary artery plaque thrombosis, and/or myocardial fibrosis.

Streptozotocin-treated *SR-B1-KO/hypoE* mice also exhibited reduced survival upon HFC diet feeding, as compared to control-treated mice fed the same diet (**Figure [1C](#F1){ref-type="fig"}**). The early death of *SR-B1-KO/hypoE* mice fed atherogenic HFC diets and of related *SR-B1/apoE double KO* mice fed normal chow diets has been attributed to their striking cardiovascular phenotypes of coronary artery atherosclerosis and myocardial infarction, which are accompanied by cardiac conductance abnormalities and reduced left ventricular function ([@B3], [@B4]; [@B18]; [@B1]; [@B15]; [@B22]; [@B21]). Therefore, we think that the earlier onset of reduced survival of STZ- compared to control-treated mice when fed the HFC diet (median survival of 6 vs 8.3 weeks, after the start of HFC feeding; **Figure [1C](#F1){ref-type="fig"}**) most likely reflects the greater severity/earlier onset of coronary artery atherothrombosis (**Figures [4J](#F4){ref-type="fig"}--[L](#F4){ref-type="fig"}**) and myocardial fibrosis (**Figures [5A](#F5){ref-type="fig"}--[I](#F5){ref-type="fig"}**). However, we cannot rule out the possibility that STZ-treatment may have had other, unanticipated and currently unknown effects, either independent of hyperglycemia or on other organ systems, that affected the survival of HFC diet fed *SR-B1-KO/hypoE* mice. On the other hand, it was recently reported that genetic induction of hyperglycemia (due to mutation of the insulin2 gene) in male *apoE-KO* mice resulted in coronary artery atherosclerosis, myocardial fibrosis, and reduced survival upon feeding a high fat, atherogenic diet ([@B32]). The similarity in phenotypes (increased coronary artery disease, myocardial infarction, and reduced survival) across two different mouse models and modes of hyperglycemia induction (high fat diet fed *Ins2-akita*/*apoE KO* mice in [@B32] and HFC diet fed, STZ-treated *SR-B1-KO/hypoE* mice in this study) suggest that these effects are likely driven by the hyperglycemia.

Conclusion
==========

Our observations that STZ-treatment increased HFC diet induced coronary artery atherothrombosis, myocardial infarction, and early death of SR-B1-KO/apoE-hypo mice suggests that this may be a useful model to study the effects of hyperglycemia on diabetic cardiomyopathy that does not require surgical ligation of coronary arteries.
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apo

:   apolipoprotein

DAPI

:   4′,6′-diamidino-2-phenylindole

HDL

:   high density lipoprotein

HFC

:   high fat/high cholesterol

HypoE

:   apoE-hypomorphic

IL-6

:   interleukin-6

KO

:   knockout

LDLR

:   low density lipoprotein receptor

SR-B1

:   scavenger receptor class b type 1

STZ

:   streptozotocin

TNFα

:   tumor necrosis factor α
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